These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30005578)

  • 1. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model.
    Song Y; Dai CL; Shinohara M; Chyn Tung Y; Zhou S; Huang WC; Seffouh A; Luo Y; Willadsen M; Jiao Y; Morishima M; Saito Y; Koh SH; Ortega J; Gong CX; Lovell JF
    Brain Behav Immun; 2024 Nov; 122():185-201. PubMed ID: 39142420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic approaches for Alzheimer's disease: Exploring active and passive vaccine progress.
    Bhadane P; Roul K; Belemkar S; Kumar D
    Brain Res; 2024 Oct; 1840():149018. PubMed ID: 38782231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Tortelli R; Galizia I; Prete C; Daniele A; Pilotto A; Greco A; Logroscino G
    Immunotherapy; 2016 Sep; 8(9):1119-34. PubMed ID: 27485083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta immunisation for Alzheimer's disease.
    Wisniewski T; Konietzko U
    Lancet Neurol; 2008 Sep; 7(9):805-11. PubMed ID: 18667360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.
    Yu YZ; Xu Q
    Hum Vaccin Immunother; 2016 Nov; 12(11):2801-2804. PubMed ID: 27379885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.